Watching Compugen; Truist Securities Out With Call Saying They Think Co's Dual TIGIT/PVRIG Approach Does Better Than Roche, Roche Data Is A Legit Signal; Perhaps Co's Dual TIGIT/PVRIG Approach Does Better; Remains Optimistic Co Is Able To Demonstrate A Differentiated Clinical Profile
Portfolio Pulse from Happy Mohamed
Truist Securities has issued a call stating that they believe Compugen's dual TIGIT/PVRIG approach outperforms Roche's. They also suggest that Roche's data is a legitimate signal, implying that Compugen's approach may be superior.
August 23, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities believes Compugen's dual TIGIT/PVRIG approach is superior to Roche's, which could positively impact Compugen's stock.
Truist Securities' endorsement of Compugen's dual TIGIT/PVRIG approach over Roche's could boost investor confidence in Compugen, potentially leading to a short-term increase in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100